Trial Profile

An Open-label, Single-arm, Multi-center, Phase II Study to Evaluate the Efficacy and Safety of RC48-ADC Combined With JS001 in Perioperative Treatment of Muscle-Invasive Bladder Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Feb 2025 According to RemeGen Media Release, data from this trial presented at American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) held in San Francisco, by Xinan Sheng from Peking University Cancer Hospital.
15 Feb 2025 Results (data cut-off date on December 3, 2024)published in the RemeGen Media Release
05 Jun 2024 According to RemeGen Media Release, data from this trial presented at the American Society of Clinical Oncology Annual Meeting (ASCO 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com